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Conjoint analysis (CA) is one approach to measuring
preferences (“utilities”) that estimates both overall pref-
erences for goods or services as well as preferences for
their specific attributes. This method, derived from eco-
nomic theory, has been widely used in many fields, as it
can provide a more flexible format for preference mea-
surement than contingent valuation or QALYs. How-
ever, CA has not been as widely used in health care. An
unresolved issue is whether CA surveys can be made eas-
ier for respondents, thereby increasing their reliability
and validity. OBJECTIVE: We conducted an experiment
to assess whether surveys designed to be easier for re-
spondents would have greater reliability and validity
than surveys developed using the standard CA approach
where all levels of attributes are allowed to vary. METH-
ODS: We surveyed 300 respondents being tested for
HIV. Respondents were asked nine questions about
whether they would choose “Test A or B” based on six
attributes (location, cost, ease of collection, timeliness
and accuracy, confidentiality, counseling). We also asked
one repeated question and one dominated question (i.e.,
where respondents should choose the obvious choice). In
the standard survey, levels of all six attributes were al-
lowed to vary. In the easier version, levels of two at-
tributes stayed constant. RESULTS: Based on prelimi-
nary data, we found a trend towards the easier survey
having greater reliability and validity, as well as lower
subjective difficulty ratings. Further analyses will exam-
ine the tradeoffs between the decreased cognitive com-
plexity of the easier survey with the statistical efficiency
lost by forcing attributes to remain constant. CONCLU-
SION: CA can provide useful information on preferences
for attributes of goods and services, including pharma-
ceuticals. By simplifying the method used to obtain pref-
erences, it may be possible to obtain more reliable and
valid responses without sacrificing statistical efficiency. 
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OBJECTIVES: This study identifies and corrects the bias
in previous reports comparing tolterodine and oxybuti-
nin XL. By adjusting for different patient populations
used, the current study provides updated results. METH-
ODS: Using recent clinical trials, correction factors were
calculated to remove bias from previous efficacy esti-
mates. That bias resulted from failure to reconcile differ-
ences in the separate studies for the two drugs. Oxybuti-
nin XL trials included known responders, all with urinary
incontinence (UI), whereas tolterodine trials examined
both naïve and previously treated patients with overac-
tive bladder (OAB), some without UI. Therefore, mea-
sures of incontinence from the oxybutinin XL trials were
adjusted to levels appropriate for a naïve and previously
treated OAB population. To assess and correct the effect
of the bias, cost-effectiveness results were recalculated
based on corrected efficacy. The pharmacoeconomic
model from the previous analysis was not described in
sufficient detail to be used. Instead, it was simplified to
generate revised cost-effectiveness measures using re-
source and cost data from the previous analysis. RE-
SULTS: When adjusted, complete continence was 22.9%
for oxybutinin XL and 24.6% for tolterodine. The sim-
plified model then estimated 6-month treatment costs to
be $1684 for oxybutinin XL and $1661 for tolterodine.
Estimated costs per continent day were $45 and $42 re-
spectively. CONCLUSIONS: Cost-effectiveness analysis
can be misleading unless biases are explicitly identified
and corrected. After adjusting for limitations in the meth-
odology previously used, no significant differences in
cost-effectiveness remain between oxybutinin XL and
tolterodine. The corrected results are consistent with
findings from trials directly comparing oxybutinin XL
and tolterodine, which also found no efficacy differences.
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OBJECTIVE: In a cost-effectiveness analysis we compared
the socioeconomic relevance of adjuvant treatment of al-
coholic patients with acamprosate with different other
possible treatments but acamprosate. The main objective
was to reveal whether this adjuvant treatment is more cost-
effective compared to the control group considering direct
and indirect costs. Further objectives were to compare
the abstinence rate one year after the onset of the study,
the duration of abstinence until the next relapse and the
number of abstinent days during the observational pe-
riod. METHODS: In a prospective multicenter cohort
study we observed 1200 alcohol dependent patients over
a period of 12 months per patient, 800 patients in the acam-
prosate cohort, 400 in the control group. RESULTS: At
the end of the study data for 766 patients could be con-
